[Featured Stock] Celltrion Rises on Emergency Use Authorization of Regkirona in Indonesia
[Asia Economy Reporter Song Hwajeong] Celltrion is showing strength following the acquisition of Emergency Use Authorization (EUA) in Indonesia for its COVID-19 antibody treatment 'Rekkirona' (generic name Regdanvimab).
As of 9:30 AM on the 20th, Celltrion was trading at 271,000 KRW, up 8,000 KRW (3.04%) from the previous day.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Treatments Available as Outbreak Accelerates... '105 Dead' and Fear Grows as American Infected"
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Mother of Three Gang-Raped on Bus in India... Outrage as Bus Driver Implicated
- "It's Only May, but Convenience Stores Know... Iced Americano at 24°C, Tube Ice Cream at 31°C: The Thermometer of the Summer Sales Boom"
On this day, Celltrion announced that on the 17th, Rekkirona received Emergency Use Authorization from the Indonesian Food and Drug Authority (BPOM). The EUA applies to adult high-risk mild and moderate COVID-19 patients confirmed positive for the virus.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
